These super-strong ASX 200 blue chip shares that could deliver 20% returns

Having a few ASX 200 blue chip shares in your portfolio is often a very good idea.

That’s because blue chips are usually established companies with strong business models and positive long-term outlooks. This can make them a great foundation to build out a portfolio from.

But which ones offer strong returns for investors over the next 12 months?

Two that brokers are tipping to rise meaningfully from current levels are listed below. Here’s what they are saying about these strong shares:

ResMed Inc (ASX: RMD)

Over at Morgans, its analysts believe that the ResMed could be an ASX 200 blue chip share to buy.

The broker currently has an add rating and $32.82 price target on its shares. This suggests potential upside of almost 20%. Its analysts commented:

While weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

Transurban Group (ASX: TCL)

The team at Bell Potter thinks that this toll road operator could be a top option for investors.

It has a buy rating and $15.90 price target on the ASX 200 blue chip share. This implies potential upside of almost 20% for investors over the next 12 month. It also expects dividend yields in the region of 5% in the coming years.

The broker recently commented:

We believe the current inflationary environment is favourable for Transurban given its inflation-linked revenue stream with annual escalators. Moreover, TCL provides low risk cash flows over the long term, with long concession duration (30+ years), and relative traffic/income resilience. The group’s current pipeline of growth projects is $3.3 billion (TCL’s share of total project cost) and further huge development opportunities are expected over the next few decades, supported by population and economic growth.

The post These super-strong ASX 200 blue chip shares that could deliver 20% returns appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• ASX blue chip shares: The best of the best for February 2024
• Buy Telstra and these ASX 200 dividend stocks
• The best ASX shares to invest $20,000 in right now
• 3 high-quality ASX 200 dividend shares to buy for a second income
• 2 ASX 200 growth shares to buy with ‘immense opportunity’ ahead

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed and Transurban Group. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/hPALuE9